Abstract: Transfusion independence in, and overall survival of, myelofibrosis patients can be improved by selecting a patient specific treatment method. A patient's baseline ferritin level can be used as a biomarker to select a first line treatment. The patient's ferritin levels during treatment can inform decisions about terminating treatment or changing treatments to maintain transfusion dependence and/or convert a patient to transfusion independent from transfusion requiring or transfusion dependent.

Abstract: The present disclosure relates to methods of treating an inflammatory disease or disorder, the method comprising: administering to a subject in need thereof a therapeutically effective amount of momelotinib (MMB) or a pharmaceutically acceptable salt thereof; and administering to the subject one or more anti-inflammatory agents, and combinations for use in treating an inflammatory disease or disorder.

Abstract: Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity.

Abstract: Herein disclosed are methods of treatment administering SRA737 as a monotherapy or in a combination therapy useful for treating patients with cancer.

Abstract: Herein disclosed are methods for treatment of cancer and methods for patient selection for administration of cancer treatment regimens comprising inhibitors of checkpoint kinase 1 (Chk1). In particular, disclosed herein are methods for identification of patients with tumors harboring genetic alterations that confer sensitivity to Chk1 inhibition.